INOLYSIS Joins THEA to Accelerate Therapeutic Innovation

We are thrilled to announce that INOLYSIS has officially joined THEA, the Athens-based startup ecosystem dedicated to supporting early-stage companies in the biotech and life sciences sector. By signing a Collaboration Agreement with THEA, INOLYSIS gains access to a dynamic environment designed to fuel innovation and growth.

Joining THEA means that INOLYSIS now benefits from:

• Tailored Services: Specialized support to address the unique challenges of early-stage biotech ventures.

• Expert Guidance: Mentorship from seasoned professionals with extensive experience in drug development and commercialization.

• Networking Opportunities: Connections with a vibrant community of startups, researchers, and investors that foster collaboration and partnerships.

• Business Development Support: Resources to accelerate our path from innovative research to real-world impact.

This collaboration strengthens INOLYSIS’ mission to advance therapeutic innovation, bridging the gap between cutting-edge research and tangible solutions for patients. Becoming part of THEA’s ecosystem provides a platform for growth, learning, and impactful collaborations, positioning us to turn our scientific discoveries into meaningful therapies faster and more efficiently.

We look forward to leveraging THEA’s resources and community to drive our research forward and make a lasting impact in the field of drug development.